Eftrenonacog Alfa | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
NEW Find Prospects
- Prospector
Drugs in Dev.
News
Blog
Market Place
Login

Eftrenonacog Alfa
Health Canada Patents

Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

Contact Supplier

Evonik Health Care is the innovation hub for leading life science companies

Contact Supplier

Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

Contact Supplier

Axplora is your partner of choice for complex APIs.

Contact Supplier

Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

Contact Supplier

pharmacompass-2-2026-02-09

Eftrenonacog Alfa

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

6 API Suppliers, 6 NDC API

6 API Suppliers
6 NDC API

FINISHED DOSAGE FORMULATIONS

26 FDF Dossiers, 20 Europe, 4 Canada, 2 South Africa

26 FDF Dossiers
20 Europe
4 Canada
2 South Africa

DIGITAL CONTENT

1 News #PharmaBuzz

1 News #PharmaBuzz

PATENTS & EXCLUSIVITIES

9 Health Canada Patents

9 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

9 All

01 9Sanofi-Aventis Canada Inc.

filter Patent Reset all filters

9 All

01 62522590

02 12899089

03 22943034

filter Product Reset all filters

9 All

01 9RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

filter Dosage Reset all filters

9 All

01 9POWDER FOR SOLUTION

filter Exp Date Reset all filters

9 All

01 62024-05-06

02 12034-03-14

03 22035-03-24

Product Main Page

01

Sanofi-Aventis Canada Inc.

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

BePharma

Not Confirmed

Sanofi-Aventis Canada Inc.

Canada

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-05-06

Date Granted : 2016-08-09

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

Brand Name : ALPROLIX

Patent Number : 2522590

Filing Date : 2004-05-06

Strength per Unit : 3000 IU / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2024-05-06

Date Granted : 2016-08-09

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Sanofi-Aventis Canada Inc.

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

BePharma

Not Confirmed

Sanofi-Aventis Canada Inc.

Canada

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-05-06

Date Granted : 2016-08-09

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

Brand Name : ALPROLIX

Patent Number : 2522590

Filing Date : 2004-05-06

Strength per Unit : 2000 IU / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2024-05-06

Date Granted : 2016-08-09

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

Sanofi-Aventis Canada Inc.

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

BePharma

Not Confirmed

Sanofi-Aventis Canada Inc.

Canada

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-05-06

Date Granted : 2016-08-09

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

Brand Name : ALPROLIX

Patent Number : 2522590

Filing Date : 2004-05-06

Strength per Unit : 1000 IU / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2024-05-06

Date Granted : 2016-08-09

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

Sanofi-Aventis Canada Inc.

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

BePharma

Not Confirmed

Sanofi-Aventis Canada Inc.

Canada

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-05-06

Date Granted : 2016-08-09

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

Brand Name : ALPROLIX

Patent Number : 2522590

Filing Date : 2004-05-06

Strength per Unit : 500 IU / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2024-05-06

Date Granted : 2016-08-09

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

Sanofi-Aventis Canada Inc.

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

BePharma

Not Confirmed

Sanofi-Aventis Canada Inc.

Canada

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-05-06

Date Granted : 2016-08-09

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

Brand Name : ALPROLIX

Patent Number : 2522590

Filing Date : 2004-05-06

Strength per Unit : 250 IU / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2024-05-06

Date Granted : 2016-08-09

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

Sanofi-Aventis Canada Inc.

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

BePharma

Not Confirmed

Sanofi-Aventis Canada Inc.

Country

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-05-06

Date Granted : 2016-08-09

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

Brand Name : ALPROLIX

Patent Number : 2522590

Filing Date : 2004-05-06

Strength per Unit : 4000 IU / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2024-05-06

Date Granted : 2016-08-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

07

Sanofi-Aventis Canada Inc.

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

BePharma

Not Confirmed

Sanofi-Aventis Canada Inc.

Country

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2035-03-24

Date Granted : 2022-06-14

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

Brand Name : ALPROLIX

Patent Number : 2943034

Filing Date : 2015-03-24

Strength per Unit : 3000 IU / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2035-03-24

Date Granted : 2022-06-14

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

08

Sanofi-Aventis Canada Inc.

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

BePharma

Not Confirmed

Sanofi-Aventis Canada Inc.

Country

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2035-03-24

Date Granted : 2022-06-14

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

Brand Name : ALPROLIX

Patent Number : 2943034

Filing Date : 2015-03-24

Strength per Unit : 4000 IU / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2035-03-24

Date Granted : 2022-06-14

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

09

Sanofi-Aventis Canada Inc.

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

BePharma

Not Confirmed

Sanofi-Aventis Canada Inc.

Country

BePharma

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2034-03-14

Date Granted : 2021-10-26

RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN

Brand Name : ALPROLIX

Patent Number : 2899089

Filing Date : 2014-03-14

Strength per Unit : 4000 IU / vial

Dosage Form : POWDER FOR SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2034-03-14

Date Granted : 2021-10-26

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.